A plan to expand patient access to Kymriah should be passed

The front of the building told a news conference, issued a statement the conference room, patient groups

It is also required to adopt maximum co-payment of 1 million won system as a presidential election pledge

While the agenda for the health insurance registration of the ultra-high-priced innovative drug Kymriah and the expansion of immuno-cancer drug Keytruda benefits have been in full swing since the afternoon of today (13th), patient groups gathered in front of the Kukje Electronic Center's Smart Work Center.

 

Patient maximum co-payment of 1 million won Of the patients' Union including patient maximum co-payment of 1 million won told the Drug Reimbursement Evaluation Committee, that the committee should pass the Kymriah insurance registration agenda and the expansion of Keytruda benefit standards, and presidential candidates insisted on the introduction of a "fast new drug health insurance system" and "Patient maximum co-payment of 1 million won." Acute lymphoblastic leukemia, lymphoma - car kymriah t treatment is Novartis Korea by taking advantage of the 'drug approval - patent linkage system' for listing on March 3, health insurance last year and on October 13, nearly seven months after conditionally cancer drugs benefit appraisal committee through.

 

Kymriah, an acute lymphocytic leukemia and lymphoma CAR-T treatment, applied for health insurance registration on March 3 last year using the "Drug Approval-Patent Linkage System" and passed the Cancer Drugs Benefit Appeal Committee on October 13, about seven months later.

 

No longer there is no cure, recurrence or refractory acute lymphocytic leukemia and lymphoma patients about 200 new cases annually.

 

Kymriah's treatment effect was a one-time treatment, with 8 out of 10 patients with end-stage acute lymphocytic leukemia and 4 out of 10 patients surviving for a long time, which is a "one-shot treatment" with only one dose, but the disadvantage was about 460 million won.

 

In addition, Keytruda, a non-small cell lung cancer immuno-cancer drug among lung cancer, has to be used from the first treatment to obtain better treatment effects, and thousands of patients are required to pay from 70 million won to 100 million won per year.

 

Therefore, Kymriah has been delayed in health insurance registration for 11 months, and Keytruda has not been able to expand its health insurance standards to primary treatments for 4 years and 4 months.

 

Patient groups appealed, "Thousands or tens of thousands of terminal acute lymphocytic leukemia and lymphoma patients and stage 4 non-small cell lung cancer patients, who had been eagerly waiting for the coverage of Kymriah and Keytruda health insurance, eventually died because they could not afford the drug price." These groups also argued in connection with the recent pledge of the ruling party's presidential candidate to apply health insurance to hair loss drugs.

 

Patient groups said, "Whether hair loss drugs are covered is a matter of comprehensive judgment considering the priority of financial use, Korea's health insurance situation, patient burden of drug prices, and cost-to-treatment effects, but if Presidential candidate Lee Jae-myung actively reviews life-related health insurance coverage, he should soon." In particular, these groups pressured the National Human Rights Commission of Korea's review of the petition filed against the Minister of Health and Welfare in October last year by some patient guardians preparing for leukemia patients and Kymriah treatment.

 

Finally, they urged the government ▲to push for patient maximum co-payment of 1 million won system to ensure rapid access to Kymriah and Keytruda to about 200 terminal acute lymphocytic leukemia and lymphoma patients and thousands of stage 4 non-small cell lung cancer patients, ▲ to be held today, drug reimbursement evaluation committee the agenda through, and ▲the government should introduce a quick registration system for new drug health insurance directly related to life.